Contact the Editorial Desk

Editorial correspondence

Peptide Care Now welcomes correspondence on the research record: a citation we have quoted inaccurately, a regulatory reference that has changed (the FDA drug status of thymosin alpha-1 compounds evolves), or a peer-reviewed study about thymulin or thymosin alpha-1 that should be included on the references page. Corrections that improve the accuracy of the digest are the most useful messages we receive.

The most actionable notes specify three things: the page they refer to, the exact passage in question, and the supporting citation — a DOI or PubMed ID wherever possible. That lets us verify a proposed change against the primary source quickly.

Editorial mailbox: editors@peptidecarenow.com

What this desk cannot do

So that no message goes unanswered for the wrong reason, several things fall outside what this site can address. Peptide Care Now is a literature digest, not a clinic or a vendor, so we cannot:

• Advise on, recommend, or comment on human use of any peptide discussed here.
• Suggest a dose, schedule, or route of administration for any individual.
• Diagnose a condition or judge whether a particular research finding applies to a particular person.
• Sell, source, recommend, or help locate any compound from any supplier.
• Interpret the 2025 TESTS null result ^[8] or any other study finding as it relates to an individual's health decisions — that is a conversation for a licensed clinician.

Readers seeking medical guidance should consult a licensed clinician in their own jurisdiction. Editorial correspondence is read carefully but responses are not guaranteed and may be delayed; the mailbox is monitored intermittently.